ArticlePakistan journal of medical sciences2025
Graves' disease in Children: A Case Report of Rare Occurrence.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' disease (GD) is an autoimmune disorder that manifests as goiter, weight loss, heat intolerance, and palpitations. It is rare in preschool-aged children (<5 years) and can lead to serious acute and long-term complications, including growth and development, if left undiagnosed. We present the case of a four-year-old Hindu Asian girl from a low socioeconomic background who presented with progressive thyroid enlargement and symptoms of excessive sweating, heat intolerance, weight loss, diarrhea, fatigue, and palpitations over six months. Examination revealed symmetrical goiter, signs of thyrotoxicosis, bilateral exophthalmos, and raised blood pressure. Laboratory investigations confirmed Graves' disease with suppressed TSH, elevated T3 and free T4, and persistently high TSH receptor antibodies (TRAb >40 IU/L). She was started on carbimazole and propranolol, resulting in clinical improvement; however, biochemical parameters, including TRAb levels, remain persistently elevated at eight months and suppressed TSH at 13 months, indicating a high risk of relapse. Long-term ATD therapy will be continued, with definitive treatment (RAI or thyroidectomy) considered if remission is not achieved after three years. This case underscores the challenges of managing Graves' disease in young children and the need for prolonged monitoring and individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.